Nasdaq, Smartsheet, Twilio, Vaxart, Zoom Video and More Friday Afternoon Analyst Calls24/7 Wall Street • 06/11/21
Vertex, Crispr Unveil More Encouraging Data From Sickle Cell, Thalassemia Gene Therapy TrialsBenzinga • 06/11/21
Vertex Pharmaceuticals stock tumbles to pace S&P 500 losers after disappointing drug trial dataMarket Watch • 06/11/21
Move Over, AMC and Dogecoin -- This Stock Could Be a Much Bigger Long-Term WinnerThe Motley Fool • 06/11/21
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual MeetingBusiness Wire • 06/11/21
Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin DeficiencyBusiness Wire • 06/10/21
CORRECTING and REPLACING Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain MutationsBusiness Wire • 06/09/21
Vertex Pharma's Trikafta Triplet Therapy Wins FDA Approval For Expanded Use In Children 6-11 Years With Cystic FibrosisBenzinga • 06/09/21
Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain MutationsBusiness Wire • 06/09/21
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should KnowZacks Investment Research • 06/07/21
Vertex: Exceptional CF Franchise And Undervalued Pipeline Send Strong Buy SignalsSeeking Alpha • 05/30/21
A Stock Market Crash May Be Near: 3 Stocks to Buy Hand Over Fist When It HappensThe Motley Fool • 05/22/21